Corconsult Rx: Evidence-based Medicine And Pharmacy

On this episode, we review the data that lead to some SGLT-2 inhibitors being used routinely in heart failure. We discuss the initial cardiovascular safety studies that initially showed heart failure benefit in this class. Then we look as some of the newer studies that have looked at empagliflozin and dapagliflozin in heart failure patients (with and without diabetes as a comorbidity). Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. To earn credit for this episode, visit the following link below to reach the post-activity test for this episode: SGLT-2 Inhibitors in HF For existing Unlimited freeCE members, this CE option is included in your membership benefits at no additional cost! Members can simply follow the link above to take the post-test and evaluation for this act